DENVER, July 15, 2015 /PRNewswire/ -- Pharmatech, a leader in CRO and SMO oncology services, today announced the appointment of Krystyna Kowalczyk as Chief Operating Officer. Reporting to CEO Rob Bohacs, Ms. Kowalczyk will enhance operations of Pharmatech in its quest for continued growth. She is expected to further enhance the company's focus and therapeutic expertise surrounding clinical Oncology trials.
"We are excited and honored to welcome Ms. Kowalczyk to our organization," said Rob Bohacs, CEO of Pharmatech. "Her passion for clinical research and experience in clinical trial management will ensure that we have a premier operations team. Her background in CRO and Site Management services will add value and vision to Pharmatech's management of our oncology network and our mission to increase patient enrollment in oncology clinical trials. She will be an invaluable asset to us."
Prior to joining Pharmatech, Ms. Kowalczyk helped lead Novella Clinical where she was the Executive Vice President of Clinical Operations. She has over 25 years of experience as a clinical research professional. Ms. Kowalczyk has built a strong background in organizational development, financial management, corporate leadership, operational strategy, project management, and customer management in the CRO sector.
The scope of Ms. Kowalczyk's background ranges from leading small niche providers to rapidly growing organizations to large global corporations. As a Novella Clinical founder she quickly built a proven track record of leadership, success, and strategic vision that will help guide the future growth and success of Pharmatech.
To learn more about Pharmatech and their work in oncology, please visit http://pharmatech.com/home/
About Pharmatech, Inc.
Pharmatech, Inc. is an oncology Contract Research Organization (CRO) that specializes in creating efficiencies in the clinical trial process. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting the inclusion of clinical trials in the spectrum of patient treatment options.
SOURCE Pharmatech, Inc.